Silalahi Todung, Alwi Idrus, Suyatna Frans, Sartika Katarina D
Division of Cardiovascular, Department of Internal Medicine, Faculty of Medicine Krida Wacana Christian University, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia.
Division Cardiovascular, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia.
Int J Angiol. 2021 Jun;30(2):132-138. doi: 10.1055/s-0040-1720969. Epub 2021 Jan 29.
Cardiovascular diseases play major roles in the health problems worldwide especially in Indonesia. Percutaneous coronary intervention (PCI) is a minimally invasive procedure with relatively low complications. However, high inflammatory response post-PCI has showed adverse events even after administration of standard medication. Previous studies showed that curcumin was able to reduce inflammatory response in adult patients with stable coronary heart disease (CHD). This article determines the efficacy of oral administration of curcumin in reducing inflammatory response post-PCI with stable CHD. A double-blind randomized controlled trial on 50 adult patients comparing curcumin and placebo was performed in Cipto Mangunkusumo General Hospital and Jakarta Heart Center within April and June 2015. Either curcumin (45 mg/day) or placebo was given 7 days prior to PCI until 2 days after PCI. Inflammatory markers (high-sensitivity C-reactive protein [hsCRP] and soluble CD40 ligand [sCD40L]) were measured in three phases (7 days prior PCI, 24 hours post-PCI, and 48 hours post-PCI). There were no significant differences in the reduction of hsCRP and sCD40L between curcumin and placebo groups in three phases of measurement. Curcumin significantly reduce the serum hsCRP ( = 0.006) and sCD40L ( = 0.002) 7 days before PCI to 48 hours post-PCI. The decrement of hsCRP (-14.2% vs. -7.4%) and sCD40L (-24.3% vs. -13.2%) from 24 to 48 hours post-PCI was higher in the curcumin group than placebo group. The administration of curcumin 45 mg dose daily for 7 days prior PCI until 48 hours post-PCI is useful in reducing inflammatory response post-PCI with stable CHD.
心血管疾病在全球尤其是印度尼西亚的健康问题中扮演着主要角色。经皮冠状动脉介入治疗（PCI）是一种微创手术，并发症相对较少。然而，PCI术后的高炎症反应即使在使用标准药物治疗后仍会出现不良事件。先前的研究表明，姜黄素能够降低稳定型冠心病（CHD）成年患者的炎症反应。本文旨在确定口服姜黄素对降低稳定型CHD患者PCI术后炎症反应的疗效。2015年4月至6月，在西托·曼古库苏莫综合医院和雅加达心脏中心对50名成年患者进行了一项双盲随机对照试验，比较姜黄素和安慰剂的效果。在PCI术前7天至术后2天，给予姜黄素（45毫克/天）或安慰剂。在三个阶段（PCI术前7天、PCI术后24小时和PCI术后48小时）测量炎症标志物（高敏C反应蛋白[hsCRP]和可溶性CD40配体[sCD40L]）。在三个测量阶段，姜黄素组和安慰剂组在hsCRP和sCD40L降低方面无显著差异。从PCI术前7天至术后48小时，姜黄素显著降低血清hsCRP（P = 0.006）和sCD40L（P = 0.002）。PCI术后24至48小时，姜黄素组hsCRP（-14.2%对-7.4%）和sCD40L（-24.3%对-13.2%）的下降幅度高于安慰剂组。PCI术前7天至术后48小时每天服用45毫克姜黄素，有助于降低稳定型CHD患者PCI术后的炎症反应。
